FDA gets power to fast-track generic drugs when first applicant stalls
H.R. 1051 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. · Filed by Nicole (Nikki) Budzinski (D-IL) · Introduced Feb 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends FDA drug approval rules to allow a second generic drug applicant to receive approval if the first applicant fails to bring their drug to market within 33 months of filing. The second applicant must certify it can market the drug within 75 days of approval and must actually do so or lose its approval. This aims to prevent first applicants from blocking generic competition by sitting on approved applications without selling.
Why we flagged it
The bill's core mechanism is procedural — it creates a conditional pathway for second-filer generic approval when first filers delay. This is a targeted fix to FDA approval sequencing, not a broad deregulation or industry carve-out.
What the text implies
- The 75-day marketing deadline is strict: failure to commercialize within that window causes automatic loss of effective approval, creating execution risk for second applicants and potentially deterring some from filing.
- The 33-month threshold may incentivize first applicants to file applications they do not intend to commercialize, then abandon them after 33 months, allowing second filers to enter — the bill does not prevent this strategic filing.
- Second applicants must certify marketing intent before approval; false certification could expose them to FDA enforcement, creating a compliance burden not borne by first applicants.
- The bill applies only to applications filed after enactment and only for drugs where no prior certification was made — this grandfathering may preserve existing blocking dynamics for older applications.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary consumers benefit from faster generic drug availability when first applicants delay market entry without cause; the 33-month threshold and 75-day marketing requirement prevent abuse while maintaining incentives for actual commercialization. The mechanism reduces artificial scarcity and pricing power.
Who stands to gain
- generic drug manufacturers (second filers)
- consumers (lower generic drug prices)
- pharmacy benefit managers and insurers (lower acquisition costs)
Named in the bill
FDA, Federal Food, Drug, and Cosmetic Act, Section 505(j), generic drug applicants, abbreviated new drug applications (ANDA)
Where it stands
- Feb 6, 2025 — Introduced · Congress.gov: “Introduced in House”
- Feb 6, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $870,000 in lobbying spend. A filing names 21 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Nicole (Nikki) Budzinski, the sponsor, reported $1,267,485 in PAC receipts in the 2026 cycle.
- Association for Accessible Medicines — $870,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,615 characters) on Sep 18, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“FDA gets power to fast-track generic drugs when first applicant stalls” QuorumCivic. https://share.quorumcivic.app/bill/119/hr1051 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.